Changes in prescribed drug doses after market introduction.
about
Beyond the Evidence of the New Hypertension Guidelines. Blood pressure measurement - is it good enough for accurate diagnosis of hypertension? Time might be in, for a paradigm shift (I)Superior efficacy of new medicines?Patient adherence to prescribed antimicrobial drug dosing regimens.Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?Can pharmacogenetics help rescue drugs withdrawn from the market?Polymorphic cytochrome P450 enzymes and post-marketing drug dosage revisions: clinical relevance to dermatologic therapies.Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study.Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006).Differences between Japan and the United States in dosages of drugs recently approved in Japan.Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans.Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX-2 inhibitor.Exploratory Analysis of Associations Between Postmarketing Safety Events and Approved Doses of New Drugs in Japan.The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study.Methods for measuring, enhancing, and accounting for medication adherence in clinical trials.The pharmacodynamic and clinical trial evidence for statin dose.Choice of comparator in active control trials of new drugs.Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response
P2860
Q24795084-EF4CA32D-F150-4514-A0BB-9DC1FBC00BB7Q33785599-A05FBFAC-CEFB-4733-BEA9-6FFF800972EFQ34403660-A1EEE0E6-CBC0-4760-9F4F-3B8F463B4D60Q35100515-52BBFB04-D191-4BE3-BFDF-65EFB2ABC533Q36596713-E8F7CC0E-D8AA-4F7F-9287-D153EBFB0F62Q36905575-085147BD-B7D3-44E9-BEAF-0AF544C369C5Q37663519-92645950-3056-4C80-A226-022B128C2EFAQ37763151-51E8D91F-5C43-4176-96B2-33B8144318CCQ37772373-ADB81ABF-79DF-497D-8436-43C4303211E9Q37952075-DE429A0E-5B58-481D-843F-88D79DC58D83Q38664871-196B5C28-14B9-45ED-8A08-1C7F2136FB29Q38771635-1EB3972A-6F07-4B15-871D-3B3AD86B6189Q39183979-4CA1F8AB-3298-49C7-AEA2-1D68F2FD494AQ39216643-60B1A6B1-8E47-4E38-969C-C3C08FB65506Q43932577-5B49DEC5-191D-4793-A2E0-FF02D30C287FQ46630774-D5D33B87-7226-4C66-BEAF-755AEDD928D3Q48114521-F7BF3337-081C-4421-B717-8FA7FF8B7CCDQ51124552-D98A8626-547F-4B18-9F5B-9F043684D351Q56828560-14A4992C-3E9C-4D31-972E-9C7FCA6C8D2C
P2860
Changes in prescribed drug doses after market introduction.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Changes in prescribed drug doses after market introduction.
@ast
Changes in prescribed drug doses after market introduction.
@en
Changes in prescribed drug doses after market introduction.
@nl
type
label
Changes in prescribed drug doses after market introduction.
@ast
Changes in prescribed drug doses after market introduction.
@en
Changes in prescribed drug doses after market introduction.
@nl
prefLabel
Changes in prescribed drug doses after market introduction.
@ast
Changes in prescribed drug doses after market introduction.
@en
Changes in prescribed drug doses after market introduction.
@nl
P2093
P2860
P356
P1476
Changes in prescribed drug doses after market introduction.
@en
P2093
Eibert R Heerdink
Hubert G Leufkens
John Urquhart
P2860
P304
P356
10.1002/PDS.745
P577
2002-09-01T00:00:00Z